Pfizer stock slipped about 0.7% to $25.19 after The Wall Street Journal reported on an inquiry looking into the suggestion ...
The report said GSK’s former head of vaccine development, Philip Dormitzer, who joined the company after working at ...
Pfizer shares are trading lower Wednesday after a Wall Street Journal report revealed that U.S. prosecutors are investigating ...
Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...
An exclusive interview with Pfizer’s Wayne Simmons on reshaping customer experience by listening to those interacting with ...
Pfizer (PFE) shares slipped on Wednesday after The Wall Street Journal reported that U.S. authorities are investigating whether or not the ...
Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?
With the market underpricing its earnings stability and future catalysts, Pfizer presents a compelling defensive investment ...
Andrew Baum, Pfizer's chief strategy and innovation officer, talked Thursday about the pharmaceutical company's drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback